COMMUNIQUÉS West-GlobeNewswire

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
09/07/2026
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus ® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to [...]
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
09/07/2026
First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with [...]
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
09/07/2026
STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
09/07/2026
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance of p38α as a [...]
TOMI Reports 124% Increase in Preliminary Second Quarter Revenue; Preliminary Six Months Revenue Combined with Open Orders Surpass Full Year 2025 Revenue
09/07/2026
FREDERICK, Md., July 09, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today reported robust preliminary second-quarter 2026 [...]
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care
09/07/2026
SHANGHAI, July 09, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, has been named to the KPMG China Healthcare 50 list, [...]
Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
09/07/2026
ORANGE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its second quarter 2026 financial results on Thursday, July 30, 2026, after market close. Following the release, [...]
Amplia Announces Publication of New FAK Inhibitor Patent Application
09/07/2026
HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia’s intellectual property portfolio supporting its FAK inhibitor program If granted, [...]
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
09/07/2026
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing First-Ever [...]
NTG Nordic Transport Group A/S - H1 2026 Conference Call
09/07/2026
NTG Nordic Transport Group A/S – H1 2026 Conference Call We expect to release the H1 2026 interim results of NTG Nordic Transport Group on the evening of August 10, 2026. A webcast and conference call will be held in [...]
New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
09/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative [...]
Dysport® est la première toxine botulinique à obtenir des résultats préliminaires positifs de phase III, à la fois dans la migraine épisodique et dans la migraine chronique.
09/07/2026
Dysport ® a obtenu des résultats préliminaires statistiquement significatifs de phase III, atteignant les critères d’évaluation principaux dans la migraine épisodique (E-BEOND) et dans la migraine chronique (C-BEOND) [...]
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
09/07/2026
Dysport ® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to [...]
Roche receives CE Mark for blood test to identify tuberculosis infection
09/07/2026
The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets. Performed on Roche’s industry-leading and widely available [...]
Cytosurge’s CellEDIT Conquers "Impossible" Genome Engineering Challenges
09/07/2026
A new peer-reviewed study validates CellEDIT’s ability to overcome cell-editing barriers, uncovering dermokine’s pivotal role in wound healing and skin cancer biology. Zurich, Switzerland – July 9, 2026 – Cytosurge AG, [...]
New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
09/07/2026
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative [...]
Outliyr's Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
09/07/2026
Outliyr's free public database catalogs more than seventy red light therapy panels and other light therapy devices, and publishes its own spectrometer measurements next to manufacturer claims for the units it has tested [...]
Range Impact Announces Vin Ferrara, MD, MBA, Has Joined the Company as Vice President, Real Estate
08/07/2026
CLEVELAND, OHIO, July 08, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing former industrial and mine [...]
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
08/07/2026
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]

Pages